Interaction Checker

Bortezomib etkileşimleri

Bortezomib (Velcade) için dizinlediğimiz FDA etiketlerinde ve bilgi sayfalarında 204 belgelenmiş etkileşim var: 33 majör, 163 orta, 5 minör ve bir etiketin anlamlı etkileşim olmadığını bildirdiği 3 çift. Aşağıdaki her kayıt, dayandığı cümleyi alıntılar. Bu ilaç sayfası bir başlangıç noktasıdır; sizin durumunuz için verilmiş bir hüküm değildir.

Etikete göre etkileşimler

Majör etkileşimler (33)

  • AprepitantCYP3A4 inhibitörüMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • ArmodafinilMSS uyarıcısıMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • BosentanCYP3A4 indükleyicisiMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Deferasiroksdemir takviyesiMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • DeksametazonkortikosteroidMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • EfavirenzantiretroviralMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Efavirenz, lamivudin ve tenofovirantiretroviralMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • EslikarbazepinantikonvülsanMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • EtravirinantiretroviralMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • FenitoinantikonvülsanMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • FenobarbitalbarbitüratMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Fentermin ve topiramatMSS uyarıcısıMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • FosfenitoinantikonvülsanMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • GriseofulvinantifungalMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • KarbamazepinantikonvülsanMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Ketokonazolazol antifungalMajör

    …caution with ketoconazole, and specifically, should not be used within at least 72 hours of treatment with ketoconazole Antineoplastics irinotecan dasatinib, lapatinib, nilotinib bortezomib, busulphan, docetaxel, erlotinib, imatinib, ixabepilone, paclitaxel, trimetrexate, vinca alkaloids Irinotecan: The potential increase in plasma concentrations of irinotecan… (Ketokonazol etiketi, İlaç etkileşimleri)

  • KlobazambenzodiazepinMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Lopinavir ve ritonavirantiretroviralMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • LorlatinibCYP3A4 indükleyicisiMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • MitapivatCYP3A4 indükleyicisiMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • MitotanCYP3A4 indükleyicisiMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • ModafinilMSS uyarıcısıMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Nafsilinpenisilin antibiyotikMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • NevirapinantiretroviralMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • OkskarbazepinantikonvülsanMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • PrimidonantikonvülsanMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • RifabutinantibiyotikMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • RifampisinantibiyotikMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • RifapentinantibiyotikMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • RitonavirantiretroviralMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • SenobamatantikonvülsanMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • SuzetrijinCYP3A4 indükleyicisiMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • TopiramatantikonvülsanMajör

    Strong CYP3A4 Inducers: Avoid concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

Orta düzey etkileşimler (163)

  • AdrenalinsempatomimetikOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • AliskirenantihipertansifOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • AmfetaminMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Amfetamin ve dekstroamfetaminMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Amiloridpotasyum tutucu diüretikOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • AmiodaronantiaritmikOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Amlodipindihidropiridin kalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Amlodipin ve atorvastatindihidropiridin kalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Amlodipin ve benazeprildihidropiridin kalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Amlodipin ve olmesartandihidropiridin kalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Amlodipin ve valsartandihidropiridin kalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Arformoterolbeta adrenerjik agonistOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Artikain ve adrenalinlokal anestezikOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Asebutololbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • AtazanavirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Atenololbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Atenolol ve klortalidonbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Azilsartananjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • BenazeprilACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Benazepril ve hidroklorotiyazidACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • BenzfetaminMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Betaksololbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Bisoprololbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Bisoprolol ve hidroklorotiyazidbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Bromfeniramin, psödoefedrin ve dekstrometorfanantihistaminikOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Budesonid ve formoterolkortikosteroidOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Bupivakain ve adrenalinlokal anestezikOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Butalbital, aspirin ve kafeinbarbitüratOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Butalbital, aspirin, kafein ve kodeinbarbitüratOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Butalbital, parasetamol ve kafeinbarbitüratOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Butalbital, parasetamol, kafein ve kodeinbarbitüratOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • DarunavirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Darunavir ve kobisistatantiretroviralOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • DaunorubisinOrta

    In a clinical trial, the first two patients given high-dose cytarabine (2 g/m 2 per day) by continuous infusion with daunorubicin and bortezomib for relapsed acute myelogenous leukemia died of ARDS early in the course of therapy. (Bortezomib etiketi, Uyarılar ve önlemler)

  • DeksmetilfenidatMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • DekstroamfetaminMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • DietilpropionMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Diltiazemkalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • DobutaminsempatomimetikOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Doksazosinalfa blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • DroksidopasempatomimetikOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • DronedaronantiaritmikOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • EfedrinsempatomimetikOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Elvitegravir, kobisistat, emtrisitabin ve tenofovirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • EnalaprilACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Enalapril ve hidroklorotiyazidACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • EnalaprilatACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Eplerenonaldosteron antagonistiOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Ergotamin ve kafeinergot alkaloidiOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Eritromisinmakrolid antibiyotikOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Etakrinik asitkıvrım (loop) diüretiğiOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • EverolimusimmünosüpresanOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Felodipindihidropiridin kalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • FendimetrazinMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • FenilefrindekonjestanOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Fenoksibenzaminalfa blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • FenterminMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • FludrokortizonkortikosteroidOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Flukonazolazol antifungalOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Flutikazon ve salmeterolkortikosteroidOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Formoterolbeta adrenerjik agonistOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • FosamprenavirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • FosaprepitantCYP3A4 inhibitörüOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • FosinoprilACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Fosinopril ve hidroklorotiyazidACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Furosemidkıvrım (loop) diüretiğiOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Guanfasinalfa adrenerjik agonistOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • HidralazinvazodilatörOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Hidroklorotiyazidtiyazid diüretikOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • İmatinibCYP3A4 inhibitörüOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • İndapamidtiyazid diüretikOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • İpratropium ve salbutamolantikolinerjikOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • İrbesartananjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • İrbesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • İsradipindihidropiridin kalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • İtrakonazolazol antifungalOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • İvakaftorCYP3A4 inhibitörüOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • İzoniazidantibiyotikOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • İzoprenalinbeta adrenerjik agonistOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • İzosorbid dinitrat ve hidralazinnitratOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Kandesartananjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Kandesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • KaptoprilACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Karvedilolbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • KinaprilACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Kinapril ve hidroklorotiyazidACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Klaritromisinmakrolid antibiyotikOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Klonidinalfa adrenerjik agonistOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Klorotiyazidtiyazid diüretikOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Klortalidontiyazid diüretikOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Labetalolbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • LenakapavirantiretroviralOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Levosalbutamolbeta adrenerjik agonistOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Lidokain ve adrenalinlokal anestezikOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • LisdeksamfetaminMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • LisinoprilACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Lisinopril ve hidroklorotiyazidACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Lofeksidinalfa adrenerjik agonistOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Losartananjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Losartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • MekamilaminantihipertansifOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • MetamfetaminMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • MetildopaantihipertansifOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • MetilfenidatMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Metolazontiyazid diüretikOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Metoprololbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Metoprolol ve hidroklorotiyazidbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Midodrinalfa adrenerjik agonistOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • MifepristonCYP3A4 inhibitörüOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • MinoksidilvazodilatörOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Mirabegronbeta adrenerjik agonistOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • MoeksiprilACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Nadololbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Nebivololbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • NefazodonantidepresanOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Nifedipindihidropiridin kalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Nikardipindihidropiridin kalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Nirmatrelvir ve ritonavirantiviralOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Nisoldipindihidropiridin kalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • NitroprussidvazodilatörOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • OksimetazolindekonjestanOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Olmesartananjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Olmesartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Olmesartan, amlodipin ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Orfenadrin, aspirin ve kafeinkas gevşeticiOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • PalbosiklibCYP3A4 inhibitörüOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • PerampanelantikonvülsanOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • PerindoprilACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Pindololbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Posakonazolazol antifungalOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Prazosinalfa blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Prilokain ve adrenalinlokal anestezikOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Propranololbeta blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • PsödoefedrindekonjestanOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • RamiprilACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • RanolazinQT aralığını uzatan ilaçOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Sakubitril ve valsartananjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Salbutamolbeta adrenerjik agonistOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Salmeterolbeta adrenerjik agonistOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • SiklosporinimmünosüpresanOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • SimetidinH2 blokeriOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • SitarabinantimetabolitOrta

    In a clinical trial, the first two patients given high-dose cytarabine (2 g/m 2 per day) by continuous infusion with daunorubicin and bortezomib for relapsed acute myelogenous leukemia died of ARDS early in the course of therapy. (Bortezomib etiketi, Uyarılar ve önlemler)

  • SolriamfetolMSS uyarıcısıOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Spironolaktonaldosteron antagonistiOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Spironolakton ve hidroklorotiyazidaldosteron antagonistiOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Suvoreksantsedatif-hipnotikOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Telmisartananjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Telmisartan ve amlodipinanjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Telmisartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Terazosinalfa blokerOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Terbutalinbeta adrenerjik agonistOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Tikagrelorantitrombosit ilaçOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

  • Tizanidinkas gevşeticiOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Torasemidkıvrım (loop) diüretiğiOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • TrandolaprilACE inhibitörüOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Triamterenpotasyum tutucu diüretikOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Triamteren ve hidroklorotiyazidpotasyum tutucu diüretikOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Umeklidinyum ve vilanterolantikolinerjikOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Valsartananjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Valsartan ve hidroklorotiyazidanjiyotensin II reseptör blokeri (ARB)Orta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Verapamilkalsiyum kanal blokeriOrta

    Hypotension: Use caution when treating patients taking antihypertensives, with a history of syncope, or with dehydration. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Vibegronbeta adrenerjik agonistOrta

    Management of orthostatic/postural hypotension may include adjustment of antihypertensive medications, hydration, and administration of mineralocorticoids and/or sympathomimetics. (Bortezomib etiketi, Uyarılar ve önlemler)

  • Vorikonazolazol antifungalOrta

    Strong CYP3A4 Inhibitors: Closely monitor patients with concomitant use. (Bortezomib etiketi, İlaç etkileşimleri)

Minör değinmeler (5)

  • DoksorubisinMinör

    …platelet count of 50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide,… (Bortezomib etiketi, Uyarılar ve önlemler)

  • PrednizonkortikosteroidMinör

    …50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin,… (Bortezomib etiketi, Uyarılar ve önlemler)

  • RituksimabimmünosüpresanMinör

    …(14%) 5 (71%) * A baseline platelet count of 50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for… (Bortezomib etiketi, Uyarılar ve önlemler)

  • SiklofosfamidimmünosüpresanMinör

    …* A baseline platelet count of 50,000/μL was required for study eligibility ‡ Data were missing at baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab,… (Bortezomib etiketi, Uyarılar ve önlemler)

  • VinkristinMinör

    …baseline for one patient In the combination study of bortezomib with rituximab, cyclophosphamide, doxorubicin and prednisone (BR-CAP) in previously untreated mantle cell lymphoma patients, the incidence of thrombocytopenia (≥ Grade 4) was 32% vs 1% for the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) arm as shown in Table 12 . (Bortezomib etiketi, Uyarılar ve önlemler)

Anlamlı etkileşim olmadığı bildirilenler (3)

  • MelfalanEtkileşim yok

    Drugs Without Clinically Significant Interactions with Bortezomib No clinically significant drug interactions have been observed when bortezomib was coadministered with dexamethasone, omeprazole, or melphalan in combination with prednisone [see Clinical Pharmacology (12.3) ] . (Bortezomib etiketi, İlaç etkileşimleri)

  • Omeprazolproton pompası inhibitörüEtkileşim yok

    Drugs Without Clinically Significant Interactions with Bortezomib No clinically significant drug interactions have been observed when bortezomib was coadministered with dexamethasone, omeprazole, or melphalan in combination with prednisone [see Clinical Pharmacology (12.3) ] . (Bortezomib etiketi, İlaç etkileşimleri)

  • Omeprazol ve sodyum bikarbonatproton pompası inhibitörüEtkileşim yok

    Drugs Without Clinically Significant Interactions with Bortezomib No clinically significant drug interactions have been observed when bortezomib was coadministered with dexamethasone, omeprazole, or melphalan in combination with prednisone [see Clinical Pharmacology (12.3) ] . (Bortezomib etiketi, İlaç etkileşimleri)

Kullandığınız her şeyi Bortezomib ile karşılaştırın. Tüm listenizi ekleyin; her çift tek seferde kontrol edilir.

Sorgulama aracında aç

Tıbbi tavsiye değildir. Şiddet derecesi sizin koşullarınızı değil, etiketin ifadesini yansıtır. “Majör” işareti gözetim altında olağan bir uygulama olabilir, “minör” işareti ise yüksek dozlarda önem kazanabilir. Bir eczacıya danışın.